Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Equity Average (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Equity Average for 15 consecutive years, with -$263.0 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 14.15% to -$263.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$263.0 million through Dec 2025, up 14.15% year-over-year, with the annual reading at -$281.6 million for FY2025, 13.04% up from the prior year.
  • Equity Average hit -$263.0 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$286.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $679.6 million in Q1 2023 to a low of -$338.4 million in Q1 2024.
  • Historically, Equity Average has averaged $76.0 million across 5 years, with a median of -$88.3 million in 2021.
  • Biggest five-year swings in Equity Average: skyrocketed 3627.52% in 2021 and later crashed 281.14% in 2024.
  • Year by year, Equity Average stood at $592.9 million in 2021, then grew by 4.86% to $621.7 million in 2022, then plummeted by 154.04% to -$336.0 million in 2023, then grew by 8.83% to -$306.3 million in 2024, then grew by 14.15% to -$263.0 million in 2025.
  • Business Quant data shows Equity Average for IRWD at -$263.0 million in Q4 2025, -$286.2 million in Q3 2025, and -$321.1 million in Q2 2025.